5 big analyst AI moves: Nvidia guidance warning; Snowflake, Palo Alto upgraded
Investing.com - JPMorgan has raised its price target on Wuxi Biologics (HK:2269) (OTC:WXXWY) stock to HK$37.00 from HK$36.00 while maintaining an Overweight rating.
The adjustment follows Wuxi Biologics’ solid first-half 2025 results, which prompted the company to increase its full-year revenue growth guidance to 14-16%, up from its previous forecast of 12-15%.
JPMorgan noted the company has entered "a clear phase of accelerated growth" with operational momentum demonstrated by an unprecedented influx of 86 new projects, with 70% in high-value ADCs and bispecifics.
The firm highlighted Wuxi Biologics’ strong PPQ pipeline, which signals potential high-margin manufacturing revenue in the medium term, along with unique research capabilities that support early-stage projects capable of generating milestone and royalty payments.
JPMorgan has raised its earnings forecasts for Wuxi Biologics by 0-4% for fiscal years 2025-2027, citing better operating efficiency that is expected to translate into higher margins.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.